Company type | Subsidiary |
---|---|
Industry | Drug discovery |
Founded | 1 November 2021 |
Founder | Demis Hassabis |
Headquarters | London |
Key people | |
Parent | Alphabet Inc. |
Website |
isomorphiclabs |
Isomorphic Labs Limited [1] is a London-based drug discovery company, which uses artificial intelligence for drug discovery. [2] [3] [4] Isomorphic Labs was founded by Demis Hassabis. [5] [3] The company was incorporated on February 4, 2021 and announced on November 5, 2021. [2] [6] It was established under Alphabet Inc. as a spin-off from its AI research lab DeepMind. [2] [3] [6] Hassabis is the CEO and founder. [3]
The company draws upon DeepMind's AlphaFold 2 technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery. [6] [7]
In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland. [6] [8]
In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly & Company to work together on AI drug discovery and research. [9]
Company type | Subsidiary |
---|---|
Industry | Drug discovery |
Founded | 1 November 2021 |
Founder | Demis Hassabis |
Headquarters | London |
Key people | |
Parent | Alphabet Inc. |
Website |
isomorphiclabs |
Isomorphic Labs Limited [1] is a London-based drug discovery company, which uses artificial intelligence for drug discovery. [2] [3] [4] Isomorphic Labs was founded by Demis Hassabis. [5] [3] The company was incorporated on February 4, 2021 and announced on November 5, 2021. [2] [6] It was established under Alphabet Inc. as a spin-off from its AI research lab DeepMind. [2] [3] [6] Hassabis is the CEO and founder. [3]
The company draws upon DeepMind's AlphaFold 2 technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery. [6] [7]
In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland. [6] [8]
In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly & Company to work together on AI drug discovery and research. [9]